|
| Press Releases |
|
 |
|
| Tuesday, August 9, 2022 |
|
|
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care |
| Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan's aging society. more info >> |
|
| Thursday, August 4, 2022 |
|
|
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022 |
| Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype. more info >> |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. more info >> |
|
|
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 |
| Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401). more info >> |
|
| Wednesday, July 6, 2022 |
|
|
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab. more info >> |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
AdsDrama Launches Short-Drama Marketing Ecosystem Launch in the Dominican Republic, Paving the Way for Digital Content Innovation
Mar 14, 2026 05:00 HKT/SGT
|
|
|
General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities
Mar 13, 2026 22:20 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00 HKT/SGT
|
|
|
CITIC Resources Deepens Dual-Engine Strategy of 'Investment + Trading', Continues to Promote High-Quality Development
Mar 13, 2026 21:01 HKT/SGT
|
|
|
uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating "Online x Offline" O2O Community Finance Strategy
Mar 13, 2026 17:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 17:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Completes Handover of WAKASHIO MARU Training Ship for National Institute of Technology, Toyama College
Mar 13, 2026 16:01 JST
|
|
|
Mitsubishi Heavy Industries to Introduce 10MW-Class Centrifugal Chiller for Next-Generation AI Data Centers in North America
Mar 13, 2026 14:10 JST
|
|
|
Revenue Triples in Four Years! Qunabox Group Reports RMB290 Million in Net Profit in 2025
Mar 13, 2026 12:27 HKT/SGT
|
|
|
Spritzer Sparkling's 'Serikan Raya, Sparkling-kan Suasana' Festive Fusion Message Promotes Togetherness and Tradition with a Light, Modern Twist 
Mar 13, 2026 12:45 JST
|
|
|
Guoquan Achieves Simultaneous Growth in Scale and Profitability, Core Operating Profit Increases by 48.2% in 2025
Mar 13, 2026 10:01 HKT/SGT
|
|
|
Founders Metals Upgrades Lower Antino to Advanced Target; Hits 65.9 m of 1.16 g/t Gold
Mar 13, 2026 04:29 HKT/SGT
|
|
|
Hitachi to deliver the world's first 550 kV gas-insulated switchgear in which the entire equipment is SF(6)-free to Chubu Electric Power Grid
Mar 12, 2026 19:40 JST
|
|
|
OrbusNeich Achieves Record-breaking Revenue, Sales Volume and Gross Profit in FY2025, Net Profit Rises to US$42 million, Final Dividend Increases by 20% to HK12 Cents per Share
Mar 12, 2026 18:07 HKT/SGT
|
|
|
Honda Announces Losses Associated with Reassessment of Automobile Electrification Strategy; Revision to Forecast for Consolidated Financial Results; and Future Direction
Mar 12, 2026 19:02 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
